Erste Group Bank Increases Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Equities researchers at Erste Group Bank lifted their FY2026 earnings per share (EPS) estimates for shares of Pfizer in a research report issued to clients and investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $2.97 per share for the year, up from their prior forecast of $2.96. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Erste Group Bank also issued estimates for Pfizer’s FY2027 earnings at $2.84 EPS.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company earned $0.63 EPS.

A number of other equities research analysts have also weighed in on the stock. HSBC reaffirmed a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Barclays started coverage on Pfizer in a research report on Thursday. They set an “underweight” rating and a $25.00 price objective on the stock. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Finally, Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $27.84.

Pfizer Stock Performance

NYSE:PFE opened at $26.66 on Monday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $25.95 and its 200 day simple moving average is $25.32. The stock has a market cap of $151.55 billion, a P/E ratio of 19.60 and a beta of 0.47. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.94.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 126.47%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after purchasing an additional 7,031,162 shares during the last quarter. State Street Corp lifted its stake in shares of Pfizer by 0.5% in the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after buying an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the last quarter. Norges Bank bought a new stake in shares of Pfizer during the second quarter valued at approximately $2,270,157,000. Finally, Morgan Stanley raised its holdings in Pfizer by 19.2% in the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.